Increased hepatic expression of the Forkhead transcription factor FoxM1B in adult mice accelerates hepatocyte proliferation after partial hepatectomy, while in hepatocytes in intact liver the transgenic (Tg) protein is inactive and has no effect on proliferation. To investigate the influence of FoxM1B on liver tumor formation, we examined the effect of sustained enrichment of FoxM1B in the hepatocytes of mice treated with a diethylnitrosamine (DEN)/phenobarbital tumor induction protocol. Tg enrichment of FoxM1B in hepatocytes did not increase the proliferation rate in normal liver tissue even when the protein was localized to the nucleus. However, it did cause an increase in the proliferation rate and size of preneoplastic and early neoplastic lesions, although having no effects on the total numbers of these lesions. As tumors progressed to hepatocellular carcinomas, the additional Tg FoxM1B protein had no effect on cell proliferation, and there was no increase in tumor burden compared to wild-type animals. This suggests that the artificial enrichment of FoxM1B in the liver, which has been suggested as a gene therapy protocol for liver dysfunction with aging, may not be tumorigenic in that organ.
Introduction
FoxM1B (previously named HFH-11, WIN or Trident) is a member of the Forkhead box (Fox) transcription factor family, whose members play important roles in regulating embryogenesis, cellular proliferation, cellular differentiation and longevity (Costa et al., 2001; Cowen, 2001; Carlsson and Mahlapuu, 2002; Kaestner et al., 2000) . Expression of FoxM1B correlates with cell proliferation (Korver et al., 1997c; Yao et al., 1997; Ye et al., 1997; Ly et al., 2000) . It is ubiquitously expressed on the mRNA level in mouse embryonic tissues, but while its expression is maintained in proliferating adult tissues, it is extinguished in differentiated cells. FoxM1B expression has also been found in a large number of cell lines, including B and T lymphoid, myeloid erythroid and several carcinoma cell lines (Korver et al., 1997a; Yao et al., 1997; Ye et al., 1997) . FoxM1B knockout mice exhibit a cell-division defect in that homozygous mutant mice die in the perinatal period and display DNA polyploidy in embryonic cardiomyocytes and hepatocytes, suggesting that FoxM1B is involved with coupling S and M phases (Korver et al., 1998) . Conditional deletion of the FoxM1B gene in adult liver indicates that the endogenous protein contributes to the positive regulation of both DNA replication and mitosis during the process of liver regeneration after injury (Wang et al., 2002a) . A transgenic (Tg) mouse model designed to express FoxM1B constitutively in liver hepatocytes showed an accelerated rate of cell cycle entry after partial hepatectomy, although the FoxM1B could not cause aberrant hepatocyte proliferation without liver injury (Ye et al., 1999) . FoxM1B overexpression in cell lines showed minimal effects, although its enrichment in HeLa cells during serum restoration led to a slight shortening of S-G2 transit times (Korver et al., 1997a; Leung et al., 2001) . Under conditions of liver regeneration, FoxM1B has also been shown to induce directly or indirectly cell proliferation factors, such as cyclin D1, cyclin B, cdc25B and cyclin A2, while reducing levels of p27 (Ye et al., 1999; Wang et al., 2001a, b) . For cyclin D1, B and cdc25B, this induction can be through FoxM1B binding sites (such as 5 0 -AGATTGAGTA-3 0 or related sequences) in the gene promoters, while other targets are likely to be indirect (Leung et al., 2001 , Yao et al., 1997 Wang et al., 2001a Wang et al., , b, 2002a . Regulation of the FoxM1B transcription factor occurs transcriptionally, post-transcriptionally and post-translationally. FoxM1B mRNA is enriched in basal cell carcinoma coinciding with the elevation of the Shh-regulated transcription factor Gli1, which can activate its promoter several fold (Teh et al., 2002) . Growth factor-dependent increases of FoxM1B mRNA, in both fibroblasts in vitro and in hepatocytes during liver regeneration in vivo, are as high as 40-fold, while the promoter region shows only a fourfold induction in transcription in response to serum (Korver et al., 1997a, b; Wang et al., 2001b) . This suggests a role for post-transcriptional regulation, supported by the fact that the deletion of 800 nucleotides of the 3 0 untranslated region of the FoxM1B transgene is sufficient to stabilize the FoxM1B mRNA in quiescent liver (Ye et al., 1999) . Post-translational regulation of FoxM1B protein can also occur in that much of the FoxM1B Tg protein is cytoplasmic in quiescent hepatocytes, but is translocated to the nucleus in response to partial hepatectomy and the growth factor-induced liver regeneration that follows (Ye et al., 1999) .
FoxM1B mRNA expression is lost with aging in both skin fibroblasts in humans and from regenerating liver in mice (Ly et al., 2000; Wang et al., 2002b) . The decrease in FoxM1B expression correlates with the decreased regenerative potential seen in livers of aged mice (and humans) (Fry et al., 1984) . Maintaining the level of FoxM1B in regenerating liver of old FoxM1B Tg mice is sufficient to restore hepatocyte progression into S phase and mitosis to levels similar to those found in young regenerating mouse liver (Wang et al., 2001b) . This suggests that the restoration of FoxM1B to aged liver may be sufficient to restore the regenerative capacity in human beings. However, an important point of consideration is that other factors that promote liver regeneration, such as transforming growth factor-a and c-myc, can also work to accelerate the formation of hepatocellular carcinoma (HCC) (Webber et al., 1994; Factor et al., 1997; Bell et al., 1999) . That and the fact that FoxM1B expression is correlated with basal cell carcinoma (but not squamous cell carcinoma) suggests that FoxM1B may be an oncogene in at least some tissue types (Teh et al., 2002) .
HCC is one of the most common cancers in the world. It is associated with hepatitis B and hepatitis C virus infection and with liver cirrhosis, and it is believed that the excessive levels of cell proliferation and inflammation associated with these phenomena lead to the formation of focal hyperplastic preneoplastic lesions (Bosch et al., 1999; Pitot, 2001) . In time, adenomas develop, which are early-stage tumors, and then finally the disease progresses to end-stage malignant HCC. A similar process of liver tumor progression also occurs in mice and rats (Mills et al., 1997; Fausto, 1999) . Many oncogenes that promote cell proliferation in the liver have been shown to cause HCC when overexpressed in the liver of Tg mice, both untreated and under various tumor induction protocols that increase tumor formation (Tamano et al., 1994; Sandgren, 1997; SantoniRugiu and Thorgeirsson, 1998; Kanzler et al., 2001) . The question asked was if FoxM1B enrichment in hepatocytes would accelerate the process of HCC formation in mice.
To investigate the influence of FoxM1B on liver tumor formation, we tested if simple enrichment of FoxM1B expression in mouse liver hepatocytes was sufficient to affect liver tumor formation. FoxM1B Tg, as well as non-Tg littermates, were subjected to a diethylnitrosamine (DEN) initiation/phenobarbital tumor promotion protocol (Tamano et al., 1994; Mills et al., 1997) . Tg overexpression of a group of oncogenes (and tumor suppressors) has been shown to affect hepatocarcinogeneis in the presence of both or one of these agents (Sell et al., 1991; Tamano et al., 1994; Bell et al., 1999; Fausto, 1999; Pierce et al., 2002) . In our experiments, cell proliferation rates were measured prior to and after hyperplastic focus, adenoma and carincoma formation, and these pre-neoplastic and neoplastic lesions were quantitated. The results showed that Tg hepatocyte expression of FoxM1B under these conditions did not increase the low hepatocyte proliferation rate in 6-week-old mice, which was surprising in light of the high level of expression of nuclear FoxM1B in these mice; nor did elevated FoxM1B increase the total number of preneoplastic hyperplastic foci or adenomas that developed. However, the Tg FoxM1B was activated in the preneoplastic and early neoplastic lesions of the Tg mice, as evidenced by increased cell proliferation rates. Remarkably, 6 months after DEN exposure, the preneoplastic and early neoplastic lesions that formed in the FoxM1B overexpressing mice were larger than those observed in the wild-type (Wt) animals, consistent with them having a faster growth rate. However, by 9 months after DEN exposure the effects of FoxM1B had been minimized. Pre-and early neoplastic lesions still showed a slightly elevated cell proliferation rate but were no longer larger. More importantly, Tg enrichment of FoxM1B in the liver had no detectable effect on the cell proliferation rate of HCCs, nor on the formation or growth of these advanced tumors. This study provides preliminary evidence that the use of gene therapy to elevate levels of FoxM1B protein so as to restore regenerative capacity to the aging or diseased liver may do so without the complications of increased incidence of HCC.
Results

Analysis of transgene expression
Construction of the Tg mice that overexpress FoxM1B in the liver has been described (Ye et al., 1999) . To verify the expression of the exogenous human FoxM1B in Tg TTR-FoxM1B CD-1 mice under the conditions used, we isolated liver RNA prior to and at various time points after exposure to the liver carcinogen DEN at 14 days of age. FoxM1B expression levels were determined by RNAse protection analysis of liver RNA with a probe that is derived from the murine form of the cDNA, but that also hybridizes to the human form ( Figure 1 ). As expected, endogenous FoxM1B mRNA is barely detect-able in Wt liver, while the level of Tg FoxM1B mRNA is at least 30 Â higher. There is a general decrease in Tg FoxM1B mRNA levels as the mice get older, but the level is still many-fold over the level of the endogenous mRNA at all time points. Western analysis of hepatic FoxM1B protein levels with an antiserum that crossreacts with the murine FoxM1B gave the same result for the 6-week time point in regard to the expression level (data not shown). There was a high-level expression of FoxM1B protein in Tg mouse liver, whereas the endogenous protein was undetectable. These findings and those that follow support the conclusion that levels of Tg FoxM1B protein are elevated many-fold in the Tg mice at all time points.
Tg FoxM1B is found in the nucleus of a large percentage of the hepatocytes in the experimental Tg mice To activate transcription, the FoxM1B protein must be nuclear (Ye et al., 1999) . We therefore performed immunohistochemical analysis to determine the localization of FoxM1B protein at the various time points. In the 2-and 6-week-old mice, 20-50% of hepatocytes on average were positive for nuclear FoxM1B expression in phenotypically normal liver tissue (Figure 2 ), whereas Wt liver displayed no FoxM1B nuclear staining. This assay used antiserum specific to the human Tg FoxM1B protein (see Material and methods). Tg mice tested with a second rabbit antiserum that reacts with both human and murine FoxM1B showed similar staining (data not shown). In Wt mice, the staining of the endogenous FoxM1B protein was less intense but still detectable in both the 2-and 6-week time points, varying from 1 to 10% of cells.
At the later time points of 25 and 42 weeks in the induction protocol, preneoplastic and neoplastic lesions occur in the livers of the mice. Immunohistochemical analysis of FoxM1B expression showed that the Tg protein was still present in the hepatocyte nuclei in phenotypically normal tissue in the Tg mice, although at a somewhat reduced rate from the 2-and 6-week-old mice. In hyperplastic foci, adenomas and carcinomas in the Tg mice, we saw increased nuclear localization of the Tg FoxM1B protein versus normal tissue (Figure 2 ). These findings in sum indicate that in the FoxM1B Tg mice subjected to the tumor induction protocol, FoxM1B was localized to the nucleus and potentially active, even at the 25-and 42-week time points, although at higher rates in the pre-and neoplastic lesions versus phenotypically normal tissue (Ye et al., 1999) .
Tg overexpression of FoxM1B increased the proliferative index of pre-and early neoplastic lesions but not normal hepatocytes or HCC
The preneoplastic hyperplastic foci and the adenomas showed a significant increase in the proliferation rate in the Tg animals at both 25 and 42 weeks of age, although the difference was more pronounced at the earlier time Figure 1 FoxM1B expression was elevated over 30 Â in FoxM1B Tg DEN-treated mice versus similarly treated Wt mice. Total liver RNA was isolated and subjected to RNAse protection assays using one probe specific to the murine and human forms of FoxM1 and one specific to the control cyclophilin mRNA. The 2-week-old mice were untreated, 6-week-old mice were treated with DEN at 14 days of age, and 25-and 42-week-old mice received the full tumor induction protocol. Each number refers to a different mouse, at 42 weeks both tumor and phenotypically normal tissue were isolated from the same mice. Arrows mark protected fragments indicative of the Tg and endogenous forms of FoxM1B and cycophilin MRNA point. These mice were subjected to the tumor induction protocol of DEN injection at day 14, followed by phenobarbital exposure after day 30 until 2 weeks prior to being killed. Results of the immunohistochemical analysis with TEC-3 antibody specific for Ki-67, a marker for proliferating cells, are shown ( Figure 3) .
All other liver tissue in the experimental mice showed no difference in proliferation rates. Carcinoma tissue in 42-week-old experimental Wt mice showed high rates of cell proliferation, which were not significantly different from the Tg mice. For normal and phenotypically normal tissue, there was no evidence for increased proliferation rates in the Tg mice at any of the time points. This was true in the 2-week-old mice that showed similar high hepatocyte proliferation rates when measured by Ki-67 immunohistochemistry (Figure 3 ). Immunohistochemical detection of incorporated 5-bromo-2-deoxyuridine (BrdU) showed similar S phase indexes for Tg versus Wt mice (6.76%70.79 versus 5.20%70.85). For the 6-week-old mice treated with DEN, cell proliferation rates were much lower, and there was not a significant difference in the rates between the FoxM1B Tg mice and the CD-1 Wt mice ( Figure 3 ). Cell proliferation as measured by immunohistochemical detection of incorporated BrdU corroborated this result in that that there was no statistically significant difference in the S phase index of FoxM1B Tg (0.26%70.06) and Wt liver (0.27%70.03). For the 25-and 42-week-old mice, phenotypically normal tissue showed very low proliferation rates in both Wt and FoxM1B Tg mice.
Interestingly, in the 6-week-old Tg FoxM1B mice, the Tg FoxM1B protein was localized to the nucleus of a similar percentage of cells on average as in the adenomas of the 25-week-old Tg mice (Figure 2 ). This was despite the fact that in the 6-week-old mice, proliferation rates were quite low (Figure 3) . The divorce between Tg FoxM1B nuclear localization and cell proliferation is demonstrated by an examination of both parameters in adjacent tissue sections from phenotypically normal tissue in a 6-week-old Tg mouse and an adenoma in a 25-week-old mouse (Figure 4 ).
The incidence of preneoplastic and neoplastic hepatic lesions were similar in FoxM1 Tg and Wt mice but there were more large lesions in Tg mice
The Tg FoxM1B transcription factor was in a large percentage of the hepatocyte nuclei in 6-week-old mice and had a stimulatory effect on cell proliferation in the early neoplastic lesions in the older mice. We therefore hypothesized that an increased nuclear level of FoxM1B may affect the formation and/or growth of early neoplastic lesions and may accelerate the timetable for carcinoma formation. Liver sections from 25-and 42-week-old Tg and Wt mice subjected to the DEN/ phenobarbital (PB) tumor induction protocol were analysed histologically for preneoplastic lesions (hyperplastic foci) and neoplastic lesions (adenomas and carcinomas). A summary of liver preneoplastic and neoplastic lesions categorized by size and type in FoxM1B Tg and CD-1 Wt mice is presented in Table 1 . Surprisingly, there was no significant difference in the total quantity of preneoplastic and neoplastic lesions of all sizes between Tg and Wt liver at either time point (Table 1) .
By contrast, the presence of the Tg FoxM1B in mouse hepatocytes did have a limited effect on the size of the early hepatic lesions -they were significantly larger in the Tg mice at 25 weeks. When hyperplastic foci were quantitated based on size, there was an increase in the larger preneoplastic lesions per liver volume in the FoxM1B mice versus the Wt mice (for lesions over 450 mm, P ¼ 0.02). The numbers of small hyperplastic foci (ro200 mm) were significantly reduced in the FoxM1B Tg liver (P ¼ 0.003). For adenomas, again large lesions (rX750 mm) were more common in the FoxM1B Tg mice than in the Wt mice (P ¼ 0.033). At the 42-week time point, there was no significant difference in size for the hyperplastic foci, adenomas and carcinomas detected. Also, the tumor burden based on percentage liver weight versus body weight was no different in the Tg versus the Wt 42-week-old experimental animals (16.072.3% versus 16.472.5%). And finally in the HCC tissue, there was no detectable effect of additional FoxM1B on tumor cell proliferation in the FoxM1B Tg versus the Wt mice (Figure 3) . Expression of endogenous FoxM1B has been correlated with neoplasia for at least one tumor type (Teh et al., 2002) . We examined levels of endogenous FoxM1B in paired phenotypically normal and tumor tissue from 42-week-old experimental mice. We saw FoxM1B induction on the mRNA level in HCC of two out of three Tg mice and two out of three Wt mice. This indicates that FoxM1B is induced with HCC tumor formation to approximately threefold the level in phenotypically normal adult tissue.
For adenomas, we used immunohistochemistry to examine FoxM1B induction. An antiserum raised against the amino-terminal portion of the FoxM1B protein that crossreacts with the murine FoxM1B was used to detect nuclear expression of endogenous FoxM1 in adenomas (Ye et al., 1999) control, we noted that the percentage of FoxM1B-positive nuclei in the hepatic adenomas was higher. It ranged from slightly above that in phenotypically normal tissue to nearly 100% of the adenoma. Collectively, these findings show that the enrichment of endogenous FoxM1B is associated with early and advanced liver tumors.
Discussion
Increases in cell proliferation are the key components in tumorigenesis of the liver -an organ that in the adult shows very low levels of cell turnover. Cell proliferation and the DNA replication that occurs with it play an important role in neoplasia acting to 'fix' mutations (converting DNA damage to mutation). If these mutations occur in genes that regulate characteristics such as resistance to apoptosis, cell mobility, dedifferentiation, immortalization and tumor vascularization,they can contribute to tumorigenesis. The importance of this coupling of DNA damage and cell proliferation to tumor formation is shown by the fact that many genotoxic agents are not carcinogenic in the adult liver but are carcinogenic in the proliferating hepatocytes of the newborn animal (Peraino et al., 1981; Mills et al., 1997) . Similarly, agents or procedures that induce liver regeneration, such as carbon tetrachloride, Hepatitis B virus or liver surgery, also serve to increase tumor formation in the presence of spontaneous or induced DNA damage (Sell et al., 1991; Mills et al., 1997; Santoni-Rugiu and Thorgeirsson, 1998) . There are many examples of Tg mice that are engineered to overexpress cell cycle stimulatory proteins in the liver resulting in increases in HCC. The most potent oncoproteins that stimulate the cell cycle induce increased rates of hepatocyte proliferation prior to the formation of neoplastic lesions, whether this be a diffuse dysplasia accompanied by much elevated rates of cell proliferation or a focal hyperplasia; examples include Figure 5 Endogenous FoxM1B expression was elevated in HCC versus matched phenotypically normal tissue from Wt and Tg FoxM1B experimental mice. Mice were treated as described in the legend of Figure 1 , and then at the various time points, total RNA was subjected to an RNAse protection assay to detect murine FoxM1B mRNA and the control cyclophilin mRNA. Each number refers to a different mouse. For Wt and FoxM1B Tg 42-week-old mice, RNA was isolated from both tumor and phenotypically normal liver tissue. Arrows mark protected fragments indicative of endogenous FoxM1B and cyclophilin mRNA cyclin D1, SV40 TAg, c-myc, transforming growth factor-a and Hepatitis B surface antigen (Webber et al., 1994; Huang and Chisari, 1995; Koike et al., 1995; Factor et al., 1997; Sandgren, 1997; Santoni-Rugiu and Thorgeirsson, 1998; Deane et al., 2001) . While continued high rates of cell proliferation in tumors after they form also play a role in tumor growth and the continued fixation of additional mutations, many experimental models point to a key role for early stimulation of cell proliferation in HCC formation.
FoxM1B enrichment in the Tg mouse liver was shown to have a proliferative effect that was specific to the intermediate stages of liver HCC formation, after initiation but prior to carcinoma formation. That this effect was specific to this neoplastic stage was supported by the fact that only adenomas and hyperplastic foci in mice exposed to the full tumor-induction protocol, and not phenotypically normal tissue or HCC in the same mice, showed an effect of additional FoxM1B. While it is formally possible that FoxM1B may increase proliferation of DEN-initiated cells, these cells are difficult to indentify (Pierce et al., 2002) and indirect evidence indicates this is unlikely. High levels of Tg FoxM1B had no overall effect on the cell proliferation rate in DENtreated liver of 6-week-old mice prior to the formation of neoplastic foci (which is normally extremely low) and it had no effect on the rate of formation of these hyperplastic foci later. This is in contrast to many things (such as carbon tetrachloride or Hepatitis B virus, and oncogenes like cyclin D1) that increase the rate of tumor initiation. These agents work at least in part, by increasing the rate of cell proliferation diffusely in the mature liver many times or by increasing the number of preneoplastic hyperplastic foci (Dragani et al., 1986; Sell et al., 1991; Mills et al., 1997; Santoni-Rugiu and Thorgeirsson, 1998; Deane et al., 2001) . FoxM1B did neither of these. As a many-fold increase in cell proliferation normally precedes tumor formation, this might explain the lack of an effect of FoxM1B enrichment on rates of adenoma formation in the Tg mice.
This study indicated that FoxM1B also had no detectable effect on the rate of tumor progression to carcinoma. Numbers of carcinomas were the same in Wt and FoxM1B Tg mice subjected to the tumor induction protocol (Table 1) . This might seem surprising in that FoxM1B did increase the proliferation rate in adenomas and foci by, on average, 100%, and the lesions tended to be larger in the Tg mice, at least in the 25-week-old mice.
If one accepts the model that hyperplastic foci can go on to form adenomas and these can transform to carcinomas, then one might expect an effect on the HCC rate due to artificial FoxM1B enrichment. However, for the Wt animals in the study, the proliferation rate for these liver lesions was already quite high (approximately 6-10% of cells in the proliferative compartment as measured by Ki-67 staining) and presumably the mutation rate was already much elevated versus normal tissue. One might speculate that in the Tg mice, the increase in the mutation rate due to the doubling of the proliferation rate during only part of the neoplastic process might not be sufficient to cause a detectable increase in the rate of HCC formation in our assay. In addition, the lack of an effect of Tg FoxM1B on HCC cell proliferation and growth would further reduce the chances of seeing an effect on hepatocarcinoma tumor burden in the liver in Tg mice.
These studies indicate that extra FoxM1B had little effect on HCC formation in the context of the DEN initiator/(PB) tumor promoter tumor induction model. Many oncogenes involved in stimulating cell proliferation, which greatly increase the rate of HCC when overexpressed in mouse transgenic models, also have additional effects on tumor properties. C-myc is angiogenic, transforming growth factor-a and SV40 TAg are antiapoptotic among other properties (SantoniRugiu et al., 1998; Santoni-Rugiu and Thorgeirsson, 1998; Thorgeirrson et al., 2000; Baudino et al., 2002) and hepatocyte growth factor, which promotes cell proliferation yet is not always tumorigenic, has multiple effects on cells, such as regulating motility (SantoniRugiu and Thorgeirsson, 1998) . This makes it difficult to discern just how important cell proliferation boosts are to HCC formation and growth. Cyclin D1, the liver oncoprotein theoretically most similar to FoxM1B in being a relatively pure inducer of proliferation, stimulates hepatocytes proliferation throughout the life of the animal -which is different than what occurs in the transgenic FoxM1B mice (Deane et al., 2001 ). Cyclin D1 a b Figure 6 Nuclear enrichment of endogenous FoxM1B in liver adenomas of Wt 25-week-old mice subjected to the DEN/PB tumor induction protocol. Representative immunohistochemistry experiments with an antiserum that crossreacts with the murine FoxM1B show (a) moderate enrichment of nuclei containing FoxM1B, in one adenoma and (b) nearly 100% positive nuclei in another, both at Â 200. Sections were counterstained with Fast Red is a strong cocarcinogen in the liver (Deane et al., 2001) . Curiously, Bcl-2, which is a cell cycle inhibitor in addition to being an inhibitor of apoptosis, blocks focus formation but not their growth after they form, yet is a potent inhibitor of HCC formation (Pierce et al., 2002) . Our findings in the context of the DEN/PB tumor induction protocol suggest that FoxM1B is not a cocarcinogen specifically in the liver. While FoxM1B can directly activate transcription of the cyclin D1, cyclin B and cdc25B genes, it has also been shown to increase expression of genes involved in DNA repair -XRCC1, MHR21spA and MHR23B, which could be antitumorigenic (Ye et al., 1999) . Importantly, this study did not address whether endogenous FoxM1B is required for HCC. Indeed suggesting that it might be, we saw endogenous FoxM1B induction in four out of six liver carcinomas and FoxM1B was enriched in one gene array analysis study of human HCC ( Figure 6 ; Okabe et al., 2001) . What the results indicate is that FoxM1B gene expression is not rate limiting for tumor formation and progression to HCC. Therefore, the usage of gene therapy of FoxM1B to restore regenerative capacity to the aging liver clinically may potentially be safe, although it requires further study.
An important additional observation of this study was the fact that FoxM1B overexpression was shown to result in nuclear protein in a large percentage of hepatocytes of the experimental animals depending on the time point, and this expression was at very high levels. Despite this, we were never able to show an effect of FoxM1B on the proliferation rate of phentoypically normal hepatocytes (Figure 3) . In 2-week-old Tg mice, the endogenous FoxM1B levels were relatively high as were the proliferation rates, and additional Tg FoxM1B had no effect (Figure 3) . By contrast, hepatocyte proliferation rates were low in 6-week-old FoxM1B Tg and Wt mice despite the presence of nuclear Tg FoxM1B in the Tg animals. At this time, no correlation was seen between the percentage of hepatocytes with nuclear FoxM1B in one section of tissue and the hepatocyte proliferation rate in the corresponding adjacent section (Figure 4 ). While nuclear localization is part of FoxM1B regulation, this result indicates that there may be additional regulation (Ye et al., 1999) . This is consistent with the observation that cotransfection of dominant-negative Ha-ras is sufficient to inhibit FoxM1B transcriptional activity without affecting its nuclear localization (M Major and RH Costa, manuscript in preparation). In contrast, the hyperplastic foci and adenomas in the 25-week-old mice Tg mice, and to a lesser degree similar lesions in the 42-week-old mice showed increased proliferation rates. In fact, a direct correlation was seen between the percentage of FoxM1B-positive hepatocytes and the hepatocyte proliferation rate among the different hyperplastic foci and adenomas (data not shown). These findings in sum are compatible with a model where nuclear FoxM1B enrichment is not rate limiting for cell proliferation in normal cells, but is rate limiting in preneoplastic and early neoplastic cells. This effect is lost in carincoma (in vivo and in vitro), possibly due to high endogenous levels of FoxM1B (Figure 3 , Korver et al., 1997a) .
The present study indicates that even after FoxM1B localizes to the nucleus in normal cells, it may not be active in stimulating cell proliferation. An important question is what is different in the hyperplastic foci and adenomas so that FoxM1B enrichment allows them to grow to larger sizes? One hypothesis is that there is a factor(s) in neoplastic tissue that is also present in regenerating liver, which permits nuclear FoxM1B to stimulate cell proliferation. Liver regeneration and liver tumor formation share many regulatory components (Fausto, 1991 (Fausto, , 1999 Fausto and Webber, 1993; Pitot, 1996; Bucher, 1997; Sandgren, 1997) . The nuclear transcription factors c-myc and the CCAAT/enhancer protein b (C/EBPb) are activated rapidly after liver injury and serve to regulate the cell proliferation aspect of liver regeneration (factors which may in turn be regulated by FoxM1B) (Ye et al., 1999; Fausto, 2000) . Growth factors interleukin-6 and possibly tumor necrosis factor also seem to be required for maximally efficient liver regeneration (Bucher, 1997; Fausto, 2000) . In addition, a host of cell cycle regulatory proteins, such as transforming growth factor-a, c-jun, c-fos, Ha-ras, raf and NF-kB are activated prior to liver regeneration and are suspected to play roles in the process (Bucher, 1997; Taub, 1997; Fausto, 2000) . While only some of these factors have been unequivocally demonstrated to be important for liver tumor formation (c-myc and transforming growth factor-a) (Sandgren et al., 1989; Jhappan et al., 1990; Lee et al., 1992) , others are enriched in tumors and are candidates to play some role in the post-translational regulation of FoxM1B proliferation control. Of course, an inhibitory factor that is lost in tumor formation and in regeneration is also a candidate to regulate FoxM1B. This study demonstrates that there are at least two components to post-translational FoxM1B activation in the TTRFoxM1B Tg CD-1 mouse: nuclear localization (Ye et al., 1999) and the further activation that allows cell proliferation to occur in pre-and neoplastic, but not normal tissue.
Material and methods
Tg mice
The generation of TTR-FoxM1B Tg CD-1 (Tg FoxM1B) mice, containing the À3 kb TTR promoter to express constitutively the FoxM1B transgene has been reported previously (Ye et al., 1999) . Heterozygous Tg FoxM1B CD-1 and Wt CD-1 mice were crossbred to generate the mice used in this study, two Tg males and 4-6 CD-1 females were used for each time point. Genotypes were determined by PCR amplification of genomic DNA obtained from mouse tails of 3-week-old mice. Primers used to amplify the transgene were similar to those described earlier (Ye et al., 1999) , while primers specific for the endogenous murine FOXM1 gene (5-GGAGCACCG-AGTgACTAATgG-3 and 5-GCCC-TgACAACATCAACTgG-3) were used as an internal control. All animal studies were performed in accordance with the guidelines of the Animal Care Policies of the University of Illinois at Chicago.
Treatment of mice
The liver tumor induction protocol was based on one published earlier with minor modifications (Tamano et al., 1994) . The 14-day-old male FoxM1B Tg and CD-1 Wt mice received an intraperitoneal injection of 5 mg/ kg DEN in sterile PBS. At 21 days of age, mice were separated and their transgenicity determined. One group of mice was euthanized at 6 weeks of age (7 Wt and 12 transgenic), between the hours of noon and 3 pm. A second group (17 Wt and 17 transgenic mice) were given water containing 0.05% of PB at 4 weeks of age for 20 weeks and then killed by carbon dioxide asphyxiation at 25 weeks of age between the hours of 10 am and noon. A third group 8 Wt and 8 transgenic was treated similarly except they were given PB for a total of 36 weeks and then killed 2 weeks later at 42 weeks of age. Body weights were recorded and livers removed, weighed and examined. The liver lobes were fixed overnight in 4% paraformaldehyde (in PBS solution pH 7.4) at 41C, paraffin embedded and cut into 4 mm sections and mounted.
Focal hepatocellular proliferative lesion stereological analysis
Focal hepatocellular proliferative lesions were detected by examination in a blind fashion of H&E-stained sections from the left lateral and medial liver lobes or all five liver lobes (42-week-old mice). Criteria for differentiating hyperplastic foci, adenomas and carcinomas have been described (Frith and Ward, 1979) . Radii of the different lesions were measured by an ocular micrometer. Only lesions with radii above 80 mm were recorded. For Table 1 , total numbers of lesions per unit volume were calculated as described earlier (Pugh et al., 1983) .
RNase protection and western analysis
RNA and protein were isolated simultaneously from frozen liver tissue using Trizol (Invitrogen) as described by the manufacturer except that part of the protein pellet was heated at 751C for 5 min in 1 Â SDS gel loading buffer to dissolve the protein. RNAse protection assays were performed as described earlier using internally 32-P labeled antisense probes for cyclophilin and murine FoxM1B exon IV sequence (Wang et al., 2001a) . Hybridization of the probes to 10 mg cellular RNA was followed by T2 RNAse digestion at 261C and separation of protected fragments with denaturing PAGE (Robles and Adami, 1998) . Under these conditions, the level of the human FoxM1B mRNA may be underestimated but by using a single probe it allows direct comparison to the level of the murine FoxM1B mRNA. For the analysis of just the endogenous FoxM1B mRNA, the T2 RNAse digestion is done at 291C so that only probe with 100% homology remains.
For Western analysis, 10% SDS-PAGE was used to separate proteins followed by electrotransfer to nitrocellulose (Schleicher and Schuell) and detection of the FoxM1 proteins with an affinity-purified antibody that crossreacts with the human and murine forms of the protein (Ye et al., 1999) . The control for protein levels was a b-actin-specific antibody (AC-15) obtained from Sigma. Detection was performed using an enhanced chemiluminescence detection system (ECL, Amersham) according to the manufacturer's recommendations.
Immunhistochemistry for FoxM1B
For immunohistochemistry analysis, 5 mm liver sections were deparaffinized with xylene and rehydrated in a graded series of ethanol washes. Endogenous peroxidase was blocked in all tissues with 3% H 2 O 2 in methanol for 15 min. Next, liver sections were treated with 20 mg/ml proteinase K in PBS for 15 min, then nonspecific background staining was blocked using 1.5% goat serum in PBS. The primary antibody used was an affinity-purified polyclonal rabbit antiserum raised to the final 144 residues at the C-terminus of human FoxM1B. Negative controls using IgG at similar concentrations showed no staining for all FoxM1B-specific antisera used in this study. Amplification of the reaction was obtained by using the Elite Vectastain ABC kit (PK6101, Vector Laboratories). Sites of immunoreactivity were detected using 3,3-diaminobenzidine as the chromagen (Vector Laboratories) and sections were lightly counterstained with Mayers hematoxylin.
Immunohistochemistry with the affinity-purified N-terminal-specific antibody, which crossreacts with human and murine forms of FoxM1B (Ye et al., 1999) , was performed as previously described except that proteinase K digestion was substituted for the microwave step, and the Vectastain ABC-AP kit (AK-5001, Vector Laboratories) followed by visualization with BCIP/NBT was used.
Hepatocyte proliferation rates
For 2-and 6-week-old mice, two methodologies were used to determine the cell proliferation index. Half of the mice were injected intraperitoneally with BrdU (Sigma) at 50 mg/g body weight, 2 h prior to euthanasia. Liver sections 5 (5 mm) were dewaxed and subjected to microwave antigen retrieval, which was followed by immunohistochemistry using mouse anti-BrdU monoclonal antibody (Roche Molecular Biochemicals) as described, except that the primary antibodies were detected using monoclonal mouse anti-mouse IgG coupled to alkaline phosphatase (AP-2000, Vector Laboratories) followed by visualization with BCIP/ NBT (Ye et al., 1999) .
For Ki-67 staining, we used the manufacturer's recommended protocol for the TEC-3 rat monoclonal anti-Ki-67 antibody (DAKO Corp., M-7249) with a few modifications. This antibody is similar to the anti-Ki-67, mouse monoclonal MIB-5, in that in hepatocyte cell proliferation assays it produces labeling indexes about two to three times BrdU labeling indexes, suggesting that it is specific for proliferating cells (Ito et al., 1998, Scholzen and Gerdes, 2000) . Briefly, the dewaxed sections, after blocking endogenous peroxidase and microwave-based antigen retrieval in 0.1 m citrate buffer at pH 6.0 for 15 min, were incubated with TEC-3 diluted 1 : 100 for 1 h at room temperature. Amplification and visualization of the reaction and counterstaining were performed as described above for FoxM1B. N ¼ 7-18 for mice and 12-22 for preneoplastic and neoplastic lesions.
For both methods, the proliferative labeling index (positive cells/total number of counted cells Â 100) was determined by the evaluation of at least 3000 hepatocytes or, in the case of focal hepatocellular proliferative lesions, 2000 hepatocytes or the entire lesion were scored.
DNA fragmentation apoptosis assay
For the determination of apoptosis rates, in situ nickend-labeling of DNA (TUNEL method) was performed (Gavrieli et al., 1992; Chen et al., 2001) . Dewaxed liver sections were treated with 20 mg/ml proteinase K in PBS for 15 min and then endogenous peroxidase was blocked with 0.1% H 2 O 2 in water. 3 0 -OH DNA termini were end labeled using terminal deoxynucleotidyl transferase and biotin-16-dUTP (Roche). Slides were incubated in TDT buffer (Gavrieli et al., 1992) , saturated in 2% bovine serum albumin, amplified by incubation with streptavidin-horseradish peroxidase for 1 h, and then detected using 3,3-diaminobenzidine as the chromagen.
Only positive cells with the atypical morphology of apoptotic hepatocytes were quantified. Total cell numbers were determined based on comparison to H&E-stained adjacent sections. The apoptotic labeling index (positive cells/total number of counted cells Â 100) was determined by counting between 1000 and 2000 hepatocytes in smaller lesions, and counting at least 2000 hepatocytes in large lesions. For neoplastic lesions n ¼ 9-15.
Statistical analysis
Statistical differences in derived cell proliferation and apoptosis rates and hyperplastic focus and adenoma numbers between groups of animals were analysed by a two-tailed Student's t-test.
